Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Lee on Immunotherapy's Future in RCC

Chung-Han (Joe) Lee, MD
Published: Thursday, Feb 02, 2017



Chung-Han (Joe) Lee, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the future of immunotherapy in the treatment landscape of renal cell carcinoma (RCC).

As of right now, Lee explains, researchers believe that immunotherapies are the way forward. The way to combine these immunotherapies in novel regimens, he adds, may be very important. These include potential combinations with immunotherapy plus VEGF-targeted therapy. Or, there may be a development of new pathways that might be significant, now that researchers better understand the genetics of kidney cancer.

Additionally, it is significant for patients to participate in a clinical trial, Lee says. This is because it allows patients to have access to medications that otherwise wouldn’t be available to them. Especially for first-line trials, there is often a lot of misinformation on whether it is a phase I, phase II, or phase III trial. Researchers hope that these experimental therapies will be better than currently available treatments.


Chung-Han (Joe) Lee, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the future of immunotherapy in the treatment landscape of renal cell carcinoma (RCC).

As of right now, Lee explains, researchers believe that immunotherapies are the way forward. The way to combine these immunotherapies in novel regimens, he adds, may be very important. These include potential combinations with immunotherapy plus VEGF-targeted therapy. Or, there may be a development of new pathways that might be significant, now that researchers better understand the genetics of kidney cancer.

Additionally, it is significant for patients to participate in a clinical trial, Lee says. This is because it allows patients to have access to medications that otherwise wouldn’t be available to them. Especially for first-line trials, there is often a lot of misinformation on whether it is a phase I, phase II, or phase III trial. Researchers hope that these experimental therapies will be better than currently available treatments.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x